These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 26828211)

  • 1. Clinical Approach to Progressive Supranuclear Palsy.
    Ling H
    J Mov Disord; 2016 Jan; 9(1):3-13. PubMed ID: 26828211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histologic tau lesions and magnetic resonance imaging biomarkers differ across two progressive supranuclear palsy variants.
    Orlandi F; Carlos AF; Ali F; Clark HM; Duffy JR; Utianski RL; Botha H; Machulda MM; Stephens YC; Schwarz CG; Senjem ML; Jack CR; Agosta F; Filippi M; Dickson DW; Josephs KA; Whitwell JL
    Brain Commun; 2024; 6(2):fcae113. PubMed ID: 38660629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson's syndrome.
    Williams DR; Holton JL; Strand C; Pittman A; de Silva R; Lees AJ; Revesz T
    Brain; 2007 Jun; 130(Pt 6):1566-76. PubMed ID: 17525140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pyramidal system involvement in progressive supranuclear palsy - a clinicopathological correlation.
    Stejskalova Z; Rohan Z; Rusina R; Tesar A; Kukal J; Kovacs GG; Bartos A; Matej R
    BMC Neurol; 2019 Mar; 19(1):42. PubMed ID: 30894142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progressive supranuclear palsy.
    Giagkou N; Höglinger GU; Stamelou M
    Int Rev Neurobiol; 2019; 149():49-86. PubMed ID: 31779824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism.
    Williams DR; de Silva R; Paviour DC; Pittman A; Watt HC; Kilford L; Holton JL; Revesz T; Lees AJ
    Brain; 2005 Jun; 128(Pt 6):1247-58. PubMed ID: 15788542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. J. Clifford Richardson and 50 years of progressive supranuclear palsy.
    Williams DR; Lees AJ; Wherrett JR; Steele JC
    Neurology; 2008 Feb; 70(7):566-73. PubMed ID: 18268249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brain volume and flortaucipir analysis of progressive supranuclear palsy clinical variants.
    Whitwell JL; Tosakulwong N; Botha H; Ali F; Clark HM; Duffy JR; Utianski RL; Stevens CA; Weigand SD; Schwarz CG; Senjem ML; Jack CR; Lowe VJ; Ahlskog JE; Dickson DW; Josephs KA
    Neuroimage Clin; 2020; 25():102152. PubMed ID: 31935638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cortical atrophy differentiates Richardson's syndrome from the parkinsonian form of progressive supranuclear palsy.
    Schofield EC; Hodges JR; Macdonald V; Cordato NJ; Kril JJ; Halliday GM
    Mov Disord; 2011 Feb; 26(2):256-63. PubMed ID: 21412832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Midbrain atrophy in patients with presymptomatic progressive supranuclear palsy-Richardson's syndrome.
    Ahn JH; Kim M; Kim JS; Youn J; Jang W; Oh E; Lee PH; Koh SB; Ahn TB; Cho JW
    Parkinsonism Relat Disord; 2019 Sep; 66():80-86. PubMed ID: 31307918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different tau pathology pattern in two clinical phenotypes of progressive supranuclear palsy.
    Jellinger KA
    Neurodegener Dis; 2008; 5(6):339-46. PubMed ID: 18349518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PET Tau Imaging and Motor Impairments Differ Between Corticobasal Syndrome and Progressive Supranuclear Palsy With and Without Alzheimer's Disease Biomarkers.
    Vasilevskaya A; Taghdiri F; Multani N; Anor C; Misquitta K; Houle S; Burke C; Tang-Wai D; Lang AE; Fox S; Slow E; Rusjan P; Tartaglia MC
    Front Neurol; 2020; 11():574. PubMed ID: 32754109
    [No Abstract]   [Full Text] [Related]  

  • 13. Does corticobasal degeneration exist? A clinicopathological re-evaluation.
    Ling H; O'Sullivan SS; Holton JL; Revesz T; Massey LA; Williams DR; Paviour DC; Lees AJ
    Brain; 2010 Jul; 133(Pt 7):2045-57. PubMed ID: 20584946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical progression of progressive supranuclear palsy: impact of trials bias and phenotype variants.
    Street D; Malpetti M; Rittman T; Ghosh BCP; Murley AG; Coyle-Gilchrist I; Passamonti L; Rowe JB
    Brain Commun; 2021; 3(3):fcab206. PubMed ID: 34541533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gradient subthalamic neurodegeneration and tau pathology in the hypoglossal nucleus as essential pathological markers of progressive supranuclear palsy - Richardson syndrome.
    Homma T; Mochizuki Y; Hara M; Kamei S; Mizutani T; Takubo H; Isozaki E; Takahashi M; Komori T; Hao H
    Rev Neurol (Paris); 2020 May; 176(5):353-360. PubMed ID: 32247606
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Messerschmidt K; Barthel H; Brendel M; Scherlach C; Hoffmann KT; Rauchmann BS; Rullmann M; Marek K; Villemagne VL; Rumpf JJ; Saur D; Schroeter ML; Schildan A; Patt M; Beyer L; Song M; Palleis C; Katzdobler S; Fietzek UM; Respondek G; Scheifele M; Nitschmann A; Zach C; Barret O; Madonia J; Russell D; Stephens AW; Koglin N; Roeber S; Herms J; Bötzel K; Bartenstein P; Levin J; Seibyl JP; Höglinger G; Classen J; Sabri O;
    J Nucl Med; 2022 Nov; 63(11):1754-1760. PubMed ID: 35422444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical value of CSF amyloid-beta-42 and tau proteins in Progressive Supranuclear Palsy.
    Schirinzi T; Sancesario GM; Di Lazzaro G; Scalise S; Colona VL; Imbriani P; Mercuri NB; Bernardini S; Lang AE; Pisani A
    J Neural Transm (Vienna); 2018 Sep; 125(9):1373-1379. PubMed ID: 29948175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progressive supranuclear palsy--parkinsonian disorder with tau pathology.
    Kowalska A; Jamrozik Z; Kwieciński H
    Folia Neuropathol; 2004; 42(2):119-23. PubMed ID: 15266787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Uncovering clinical and radiological asymmetry in progressive supranuclear palsy-Richardson's syndrome.
    Picillo M; Tepedino MF; Abate F; Ponticorvo S; Erro R; Cuoco S; Oksuz N; Di Salle G; Di Salle F; Esposito F; Pellecchia MT; Manara R; Barone P
    Neurol Sci; 2022 Jun; 43(6):3677-3682. PubMed ID: 35106692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluorodeoxyglucose positron emission tomography in Richardson’s syndrome and progressive supranuclear palsy-parkinsonism.
    Srulijes K; Reimold M; Liscic RM; Bauer S; Dietzel E; Liepelt-Scarfone I; Berg D; Maetzler W
    Mov Disord; 2012 Jan; 27(1):151-5. PubMed ID: 22359740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.